NO20041759L - Kopolymerer for suppresjon av autoimmunsykdommer samt deres anvendelse - Google Patents

Kopolymerer for suppresjon av autoimmunsykdommer samt deres anvendelse

Info

Publication number
NO20041759L
NO20041759L NO20041759A NO20041759A NO20041759L NO 20041759 L NO20041759 L NO 20041759L NO 20041759 A NO20041759 A NO 20041759A NO 20041759 A NO20041759 A NO 20041759A NO 20041759 L NO20041759 L NO 20041759L
Authority
NO
Norway
Prior art keywords
suppression
copolymers
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
NO20041759A
Other languages
English (en)
Other versions
NO337092B1 (no
Inventor
Jack L Strominger
Masha Fridkis-Hareli
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of NO20041759L publication Critical patent/NO20041759L/no
Publication of NO337092B1 publication Critical patent/NO337092B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
NO20041759A 2001-10-03 2004-04-29 Aminosyrekopolymerer for suppresjon av autoimmunsykdommer, preparat og enhetsdoseform samt deres anvendelse NO337092B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32670501P 2001-10-03 2001-10-03
PCT/US2002/031399 WO2003029276A2 (en) 2001-10-03 2002-10-03 Copolymers for suppression of autoimmune diseases, and methods of use

Publications (2)

Publication Number Publication Date
NO20041759L true NO20041759L (no) 2004-04-29
NO337092B1 NO337092B1 (no) 2016-01-18

Family

ID=23273317

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20041345A NO20041345L (no) 2001-10-03 2004-03-31 Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse
NO20041759A NO337092B1 (no) 2001-10-03 2004-04-29 Aminosyrekopolymerer for suppresjon av autoimmunsykdommer, preparat og enhetsdoseform samt deres anvendelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20041345A NO20041345L (no) 2001-10-03 2004-03-31 Kopolymerer for undertrykkelse av autoimmune sykdommer og fremgangsmate for anvendelse

Country Status (12)

Country Link
US (3) US7381790B2 (no)
EP (2) EP2123669A1 (no)
JP (3) JP5010798B2 (no)
AU (1) AU2002362445B2 (no)
CA (1) CA2462459C (no)
DE (1) DE02800437T1 (no)
HU (1) HUP0401863A3 (no)
IL (2) IL161121A0 (no)
NO (2) NO20041345L (no)
NZ (1) NZ532199A (no)
WO (1) WO2003029276A2 (no)
ZA (1) ZA200402601B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
IL157073A0 (en) * 2001-01-24 2004-02-08 Harvard College Therapeutic peptides for demyelinating conditions
BRPI0508382A (pt) * 2004-03-01 2007-07-31 Peptimmune Inc métodos e composições para tratamento de doenças auto-imunes
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20090275496A1 (en) * 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
BRPI0510738A (pt) * 2004-05-07 2007-11-20 Peptimmune Inc métodos de tratar doenças com copolìmeros aleatórios
JP2009536157A (ja) * 2006-04-13 2009-10-08 ペプチミューン，インコーポレイテッド エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
US9533037B2 (en) 2007-10-16 2017-01-03 Declion Holdings Llc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
WO2009075854A2 (en) * 2007-12-10 2009-06-18 Peptimmune Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3536333B1 (en) 2010-01-04 2022-08-03 Mapi Pharma Limited Depot system comprising glatiramer acetate
ES2601892T3 (es) * 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10144778B2 (en) 2014-03-12 2018-12-04 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
EP3170836B1 (en) * 2015-11-23 2018-10-24 Chemi SPA Rp-hplc analysis of complex polypeptide mixtures
CA3029654A1 (en) * 2016-07-01 2018-01-04 Declion Holdings Llc Amino acid copolymer compositions and uses thereof
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
EP4243834A2 (en) * 2020-11-10 2023-09-20 Palena Therapeutics, Inc. Compositions of embedded epitope random peptides (eerp) for treatment of immune-mediated conditions, and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3052655A (en) * 1958-08-01 1962-09-04 Sidney W Fox Thermal polymerization of amino acid mixtures containing aspartic acid or a thermal precursor of aspartic acid
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US4996292A (en) * 1989-06-30 1991-02-26 Fox Sidney W Self-sealing artificial skin comprising copoly-alpha-amino acid
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5734023A (en) * 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
NZ333946A (en) 1996-08-05 2000-09-29 Harvard College MHC binding peptide oligomers
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
EP1066295A2 (en) 1998-03-23 2001-01-10 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
WO2000005250A1 (en) * 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
IL140592A0 (en) * 1998-07-23 2002-02-10 Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
DE69940888D1 (de) * 1998-09-25 2009-06-25 Yeda Res & Dev Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
IL157073A0 (en) 2001-01-24 2004-02-08 Harvard College Therapeutic peptides for demyelinating conditions
AU2002317071B2 (en) * 2001-06-22 2008-01-31 The Hospital For Sick Children Antimicrobial peptides
US8017166B2 (en) 2004-11-01 2011-09-13 Steven Amory Twitty Method of producing stackable low-fat snack chips

Also Published As

Publication number Publication date
JP5525749B2 (ja) 2014-06-18
EP1438061B1 (en) 2016-05-11
US20040038887A1 (en) 2004-02-26
IL161121A (en) 2010-11-30
US8017125B2 (en) 2011-09-13
NZ532199A (en) 2008-02-29
HUP0401863A2 (hu) 2004-12-28
ZA200402601B (en) 2005-07-27
EP1438061A4 (en) 2005-02-23
JP2005511518A (ja) 2005-04-28
HUP0401863A3 (en) 2012-09-28
CA2462459C (en) 2007-12-18
JP2012162545A (ja) 2012-08-30
DE02800437T1 (de) 2004-11-11
IL161121A0 (en) 2004-08-31
AU2002362445B2 (en) 2006-09-21
EP1438061A2 (en) 2004-07-21
JP2009185057A (ja) 2009-08-20
WO2003029276A2 (en) 2003-04-10
EP2123669A1 (en) 2009-11-25
US20080241099A1 (en) 2008-10-02
US7381790B2 (en) 2008-06-03
CA2462459A1 (en) 2003-04-10
JP5010798B2 (ja) 2012-08-29
NO20041345L (no) 2004-03-31
US20110286959A1 (en) 2011-11-24
NO337092B1 (no) 2016-01-18
US9028835B2 (en) 2015-05-12
WO2003029276A3 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
NO20041759L (no) Kopolymerer for suppresjon av autoimmunsykdommer samt deres anvendelse
DE60235896D1 (de) Verzögerte freigabe von mikrokristallin peptidsuspensionen
PL373156A1 (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
EE200100659A (et) Diaminotiasoolid ja nende kasutamine proteiinikinaaside pärssimiseks
PT984957E (pt) Novas formas de s-omeprazole
ID30590A (id) Celana sekali pakai jenis-celana pendek
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DK1392292T3 (da) Pyranoindazoler og deres anvendelse til behandling af glaukom
FI20010558A (fi) Kappaleiden paikannus
HUP0402536A3 (en) Novel crystalline forms of meloxicam and the preparation and interconversion methods thereof
NO20041968L (no) Anvendelse av cystationin
HUP0301551A3 (en) New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes
DE60223540D1 (de) Mundschutz und mundschutzfolie
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
GB2399425B (en) Improving stability and response of control systems
AR027832A1 (es) Metodos de tratamiento y metodos de rastreo de farmacos
AR028438A1 (es) Composiciones de antitranspirantes y/o desodorantes
EP1461450A4 (en) T-BET COMPOSITIONS AND METHOD OF USE THEREOF
PL369736A1 (en) New medicinal compositions on the basis of anticholinergic agents and egfr kinase inhibitors
NO20042476L (no) Anvendelse av desoxypeganin for behandling av klinisk depresjon
AU2003207941A8 (en) Pigment epithelium derived factor from human plasma and methods of use thereof
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
EP1416889A4 (en) REDUCED INCISION LENS AND USE THEREOF
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
AU2003302271A8 (en) Methods of treating and/or preventing autoimmune diseases

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees